CCO Interactive Case Challenges

CCO Interactive Case Challenges: Treatment of Metastatic Breast Cancer

Interactive Case Challenges

Management of a 46-Year-Old Woman With Estrogen Receptor–, Progesterone Receptor–, and HER2-Receptor–Negative Metastatic Breast Cancer

Faculty:

Kathy D. Miller, MD headshot
  • Kathy D. Miller, MD

CME CREDIT INFORMATION

Release Date: 10/05/06

Expiration Date: 10/04/07


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Test your ability to manage a premenopausal, white female legal assistant from the Midwest with tumor characteristics that suggest aggressive disease and a poor prognosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe issues related to management of metastatic breast cancer patients who have previously received anthracyclines and taxanes
  • Evaluate the efficacy and safety of cytotoxic agents in metastatic breast cancer
  • Discuss the integration of biologic therapy with chemotherapy in patients with metastatic breast cancer

Management of a 58-Year-Old Woman With Estrogen Receptor-Positive, HER2-Positive, Node-Negative Metastatic Breast Cancer

Faculty:

Clifford A. Hudis, MD headshot
  • Clifford A. Hudis, MD

CME CREDIT INFORMATION

Release Date: 10/05/06

Expiration Date: 10/04/07


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Test your ability to manage a relatively healthy postmenopausal 58-year-old female for whom liver nodule biopsy confirms the diagnosis of ER-positive breast cancer that is also HER2-positive by fluorescence in situ hybridization (FISH).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe appropriate initial management of a postmenopausal woman with ER- and HER2-positive metastatic breast cancer (MBC)
  • List options for further treatment of a patient with ER- and HER2-positive MBC who progresses following standard therapy
  • Discuss management of ER- and HER2-positive MBC in a patient who does not respond to hormonal therapy
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.